186 results on '"Eclache, Virginie"'
Search Results
2. Molecular landscape of mature B‐cell lymphoproliferative disorders with BCL3‐translocation: A Groupe Francophone de Cytogénétique Hématologique (GFCH)/French Innovative Leukemia Organization (FILO) study.
3. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
4. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53
5. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
6. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia
7. Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia
8. The Broad Spectrum of TP53 Mutations in CLL : Evidence of Multiclonality and Novel Mutation Hotspots
9. Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
10. “Double‐hit” chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain
11. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
12. TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
13. The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high‐risk clonal cytopenia of unknown significance.
14. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
15. Characterisation of a New Clinical Presentation of Chronic Lymphocytic Leukemia with Symptomatic Nasopharyngeal Mucosa Involvement
16. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis
17. Old DAT and new data: Positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients
18. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization ( FILO )
19. KMT2A-ARHGEF12, a Therapy Related Fusion with Dismal Prognosis.
20. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).
21. Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
22. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving and MYC and TP53
23. Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement
24. Abstract 608: The MPS1 inhibitor S81694 is active in acute myeloid leukemia (AML)
25. Prevalence, distribution and predictive value of XPO1 mutation in a real‐life chronic lymphocytic leukaemia cohort
26. Réponse aux inhibiteurs de tyrosines kinases des patients avec néoplasies myéloïdes et transcrits rares
27. Évolution de l’hématopoïèse clonale à long terme dans le contexte d’allogreffe
28. The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants
29. A primitive plasma cell leukemia with immunoglobulin (Ig) E
30. Cytogenetic complexity in chronic lymphocytic leukemia : definitions, associations, and clinical impact
31. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving and MYC and TP53
32. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact
33. The CADM1tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
34. Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group
35. A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)
36. t(5;11)(q33;q13) NUMA1/PDGFRB a novel fusion
37. High Frequency of Mutations in BTK and PLCG2 in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Therapy
38. TP53, XPO1 and ATM Mutations Exclusive Distribution in the Adverse Prognosis Chronic Lymphocytic Leukemia (CLL) Group
39. Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies
40. Nouvelles données génétiques dans les leucémies aiguës promyélocytaires de l’adulte de plus de 60 ans
41. L’azacitidine est-elle bénéfique aux myélodysplasies de haut risque avec monosomie 7 ?
42. Difficulties of classifying an acute myeloid leukemia occurring during hemolytic crisis
43. Value of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.
44. Classification of myelodysplastic syndromes 2015
45. Supériorité du ponatinib sur l’allogreffe dans les leucémies aiguës positives pour le Philadelphie avec mutation T315I
46. Mauvais pronostic des leucémies aiguës lymphoblastiques Ph-like chez l’adulte
47. La présence d’hématopoïèses clonales de signification indéterminées permet-elle de prédire la survenue d’une hémopathie secondaire à un traitement pour cancer chez les patients de plus de 70 ans ?
48. Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases
49. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYCand TP53
50. À propos d'un cas de leucémie plasmocytaire primitive à IgE.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.